secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001703057-26-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera doses first patients in Phase 2 trial of ABCL635 for menopausal vasomotor symptoms
--------------------------------------------------------------------------------

- ABCL635, a non-hormonal candidate for moderate-to-severe vasomotor symptoms (VMS) of menopause, advances to Phase 2.
- Phase 2 is a randomized, double-blind, placebo-controlled study in 80 postmenopausal women.
- Top-line clinical results for both Phase 1 and Phase 2 expected in Q3 2026.
- Phase 1/2 redesignation based on interim safety, tolerability, and pharmacodynamic data from healthy volunteers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000003/0001703057-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000003/abcl-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer